If you are developing a radiopharmaceutical drug and preparing for an Investigational New Drug (IND) filing, understanding nonclinical requirements set by the Food and Drug Administration (FDA) is essential, and more manageable than you might expect. The radiopharmaceutical space is rapidly evolving, and emerging developers need a clear picture of the regulatory and commercial pathway before committing resources.
Nonclinical requirements for radiopharmaceuticals are not one-size-fits-all. The FDA distinguishes meaningfully between radiodiagnostic and radiotherapeutic programs, and the type of program you are developing has direct implications for the scope, cost, and sequencing of your nonclinical package. Understanding where those differences lie is the first step toward building a strategy that satisfies regulatory review without over-investing in studies you don’t need.
New to the radiopharmaceutical development landscape? Read: Leveraging Development Opportunities in Radiopharmaceuticals
Nonclinical Requirements for Microdose Radiodiagnostics
Radiodiagnostic imaging relies on the administration of radiolabeled compounds to visualize and characterize biological processes in vivo. Depending on the types of radiation emitted, administered doses can range from nanograms to micrograms. Typically, these drugs are either degraded/metabolized or excreted intact. No pharmacologically active metabolites are formed. Even if a metabolite had pharmacological effects, those effects would only occur at doses far exceeding those needed for diagnostic purposes.
Some current FDA-approve radiodiagnostics include In-111-pentetreotide (OctreoScan™), Ga-68-DOTATOC (edotreotide Ga-68 Injection), and Fluciclovine F-18 injection (Axumin®).
While the radiation doses delivered by diagnostic imaging modalities vary widely, radiopharmaceutical diagnostic drugs occupy a distinct category defined not only by their radiation profile, but by the exceptionally small mass doses involved. This distinction has direct regulatory implications.
Per the CDER Guidance for Industry — Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations (August 2018), a microdose is defined as 1/100th of the dose required for a pharmacologic effect, with a maximum of ≤100 micrograms (µg). The maximum dose for protein products is ≤30 nanomoles (nmol).
Unlike a typical small molecule or biologic, radiodiagnostic drugs follow a simplified, but highly specific, nonclinical development pathway as a result of this low dose ceiling.
Pharmacology and Target Binding Studies
As with any IND, all pharmacological, pharmacokinetic, and toxicological properties must be characterized. For radiodiagnostic agents specifically, both benchtop and animal studies — including receptor/target/off-target profiling and imaging properties — are required. Standard safety pharmacology studies are not typically required for radiodiagnostic agents, though this remains product-specific.
PK, ADME, and Dosimetry
The pharmacokinetic (PK) behavior and absorption, distribution, metabolism, and excretion (ADME) properties and dosimetry should also be characterized. Potential drug interactions must also be assessed before exposing large numbers of subjects to the investigational compound.
A Developmental and Reproductive Toxicity (DART) waiver should generally be requested for radiodiagnostic agents due to the inherent radiation risk to the fetus. This is standard practice and FDA routinely accepts such waivers for this drug class.
Nonclinical Requirements for Radiotherapeutics
Radiopharmaceuticals intended for therapeutic use, such as targeted radionuclide therapies for cancer, also have a comparatively simple nonclinical development path compared to most new drugs.
However, the nonclinical requirements for radiotherapeutics are meaningfully more extensive than those for radiodiagnostic agents, for one key reason: the amount of ligand administered in a therapeutic program is typically far greater than in a diagnostic one. This means FDA requires additional characterization of both the pharmacological and toxicological effects of the ligand itself.
Current FDA-approved therapeutic examples include Lutathera (Lu-177-DOTATATE) for NETs and Pluvicto (177Lu-PSMA-617) for metastatic prostate cancer, both useful benchmarks for developers designing oncology programs.
If prior experience or publicly available data exists for the nonradioactive component(s) of the radiopharmaceutical, this may — but does not always — reduce nonclinical requirements. PET radiopharmaceutical experts can help you assess what prior data applies to your specific program.
Pharmacology, Biodistribution and Dosimetry in Animals
Pharmacological studies focus on efficacy/proof-of-concept and target/off-target binding of the radioactive compound. These data, combined with PK, biodistribution, and dosimetry data in animals, are used to estimate human organ radiation absorbed doses. With systemically administered radiopharmaceuticals, the radiation dose to each organ is determined primarily by the agent’s PK and biodistribution, as well as the type(s) of radiation emitted. Consequently, the risk of radiation injury to a given organ is determined by its intrinsic radiosensitivity, the amount of radioactivity present, and the radioactivity in surrounding organs over time.
Ligand Toxicology
Unlike radiodiagnostic programs, radiotherapeutic programs require dedicated toxicology studies on the ligand component. The scope of these studies is informed by the amount of ligand administered and any existing safety data for the nonradioactive component.
Late Radiation Toxicity: When Long-Term Studies Are Warranted
An assessment of late radiation toxicities is warranted when patients have a long life expectancy that could be affected by delayed radiation adverse effects. In these cases, toxicity studies in animals may be acceptable when human testing is not ethically feasible. This consideration is generally not a factor in radiodiagnostic development.
Diagnostic vs. Therapeutic: Key Nonclinical Requirements at a Glance
| Nonclinical requirement | Radiodiagnostic agent | Radiotherapeutic agent |
| Receptor / target profiling | ✓ Required | ✓ Required |
| Off-target binding studies | ✓ Required | ✓ Required |
| PK / ADME characterization | ✓ Required | ✓ Required |
| Dosimetry in animals | ✓ Required | ✓ Required |
| Standard safety pharmacology | Typically waived; product-specific | Product-specific |
| Ligand toxicology studies | ✗ Not typically required | ✓ Required |
| DART waiver | ✓ Typically granted | Case-by-case |
| Late radiation toxicity assessment | ✗ Not typically required | When life expectancy warrants |
| Drug interaction assessment | ✓ Required | ✓ Required |
| Proof-of-concept efficacy studies | ✗ Not required | ✓ Required |
Related Reading: Three Key Considerations for Navigating FDA Oversight in Radiopharmaceutical Development
Frequently Asked Questions: Radiopharmaceutical IND Filing
Do I need a full toxicology package for a radiodiagnostic IND?
No. Because of the microdose threshold (≤100 µg, or 1/100th of the pharmacologically active dose), radiodiagnostic drugs follow a simplified nonclinical path. Standard safety pharmacology studies are typically not required, and a DART waiver is usually granted. A regulatory gap analysis can confirm exactly what your program needs before you commit to studies.
What nonclinical studies are required before a radiopharmaceutical IND can be filed?
At minimum: pharmacology studies (receptor/off-target profiling, imaging characterization), PK/ADME data, dosimetry, and a drug interaction assessment. For therapeutics, ligand toxicology and proof-of-concept efficacy data are also required.
Related Reading: Navigating the CMC Journey in Radiopharmaceuticals
Does prior data on the nonradioactive component reduce my nonclinical burden?
It may, but not automatically. If robust published or proprietary data exists for the cold ligand, FDA may allow a reduced nonclinical package, but this must be confirmed with your regulatory strategy team before relying on it.
When should I consider requesting an FDA meeting to align my nonclinical strategy?
Early. A Type C or pre-IND meeting can prevent costly missteps.
Related Reading: Behind the Scenes of a Productive Nonclinical Type C Meeting Strategy
Work with an Experienced Radiopharmaceutical Regulatory Partner
Designing an efficient, review-ready nonclinical package requires deep familiarity with both the science and the regulatory landscape. Getting it right the first time saves significant time and cost on the path to IND submission and eventual approval. The nonclinical choices you make early don’t just satisfy FDA review, they shape your asset’s value, partnership potential, and time-to-market.
The Facet Life Sciences team has guided emerging developers through IND submissions for both radiodiagnostic and radiotherapeutic programs. Grounded in regulatory expertise and a genuine commitment to your commercial success, we help innovators build streamlined nonclinical strategies that align with regulatory and market expectations.
gET sOCIAL